SBIR Funding BioRankings has secured NIH SBIR funding (Phase I and II) to advance statistical methods and metabolomics software, signaling strong grant credibility and potential for collaborative projects or contract work aligned with government-funded initiatives.

Early-Stage Focus With a small team (2-10 employees) and a history of collaboration across academia, biotech startups, and legal/finance due diligence, there is a clear opportunity to offer scalable consulting engagements and modular services to small biotech firms and startups seeking statistical rigor without large vendor overhead.

Metabolomics Edge Recent product launches in untargeted metabolomics detection and multi-omics analytics suggest demand for advanced statistical methods; target biotech startups and contract research organizations that need rapid, rigorous metabolomics and microbiome analyses.

Strategic Partnerships Existing collaboration with Domino Data Lab and NIH funding indicate receptiveness to platform-enabled analytics; sales opportunities exist in offering integrated data science platforms, hosted workflows, and joint projects that pair BioRankings’ statistics with enterprise data platforms.

Industry Reach Serving academia, biotech startups, big pharma/ag, and finance due diligence creates cross-industry access points; propose multi-pronged outreach campaigns highlighting risk assessment, due diligence analytics, and statistically driven decision support for fundraising, clinical development, and regulatory submissions.